<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">Colorectal cancer</z:e> is the third leading cause of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-related mortality in the world </plain></SENT>
<SENT sid="1" pm="."><plain>The main cause of <z:hpo ids='HP_0011420'>death</z:hpo> because of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> is <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">hepatic metastases</z:e>, which can be treated using isolated hepatic perfusion (IHP), allowing treatment of colorectal <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> with various methods </plain></SENT>
<SENT sid="2" pm="."><plain>In this study, we present a novel potent multimodality strategy comprising humanized <z:hpo ids='HP_0011420'>death</z:hpo> receptor 4 (DR4) antibody mapatumumab in combination with <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> and <z:hpo ids='HP_0001945'>hyperthermia</z:hpo> to treat human <z:hpo ids='HP_0003003'>colon cancer</z:hpo> cells </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="31941">Oxaliplatin</z:chebi> and <z:hpo ids='HP_0001945'>hyperthermia</z:hpo> sensitized <z:hpo ids='HP_0003003'>colon cancer</z:hpo> cells to mapatumumab in the <z:hpo ids='HP_0001427'>mitochondrial</z:hpo>-dependent apoptotic pathway and increased reactive oxygen species (ROS) production, leading to Bcl-xL phosphorylation at serine 62 in a c-jun-<z:chebi fb="0" ids="29318,29339">NH2</z:chebi>-kinase (JNK)-dependent manner </plain></SENT>
<SENT sid="4" pm="."><plain>Overexpression of Bcl-xL reduced the efficacy of the multimodality treatment, whereas phosphorylation of Bcl-xL decreased its antiapoptotic activity </plain></SENT>
<SENT sid="5" pm="."><plain>The multimodality treatment dissociated Bcl-xL from Bax, allowing Bax oligomerization to induce <z:chebi fb="1" ids="18070">cytochrome c</z:chebi> release from mitochondria </plain></SENT>
<SENT sid="6" pm="."><plain>In addition, the multimodality treatment significantly inhibited <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> xenografts' <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>The successful outcome of this study will support the application of multimodality strategy to colorectal <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">hepatic metastases</z:e> </plain></SENT>
</text></document>